Humacyte, Inc

Vascular diseases, repair of vascular trauma, and disorders of the vascular system represent substantial therapeutic areas for the applications of regenerative medicine. Despite advances in endovascular repair, surgical intervention, and disease management, medical challenges to adequately manage sustainable vascular access, atherosclerosis, and regenerative medicine applications continue to be prominent health challenges.

Humacyte’s human acellular vessel (HAV) is being studied initially for vascular access, and Humacyte plans to seek approval of this use for a first indication. If approved, Humacyte’s HAV could be a therapeutic alternative to current arterio-venous prosthetic grafts, with the potential to overcome complications of PTFE and animal-derived tissue grafts.

Humacyte’s HAV has the potential to be applied to a range of future vascular settings beyond the initial indication for vascular access. Potential applications include peripheral vascular grafts (above and below the knee), arterial trauma, and vascular applications that require smaller lumen vessels.

Because there are over 4,000 conduits in the human body, HAV also represents a potential technology platform that can be expanded beyond vascular settings. Humacyte and licensees have developed preliminary proof of concept data in selected therapeutic areas, including esophagus and trachea replacement, as well as other shapes and conformations.